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Abstract Pancreatic cancer is highly resistant to the
currently available chemotherapeutic agents. Less than 5%
of patients diagnosed with this disease could survive
beyond 5 years. Thus, there is an urgent need for the devel-
opment of novel, eYcacious drugs that can treat pancreatic
cancer. Herein we report the identiWcation of artesunate
(ART), a derivative of artemisinin, as a potent and selective
antitumor agent against human pancreatic cancer cells in
vitro and in vivo. ART exhibits selective cytotoxic activity
against Panc-1, BxPC-3 and CFPAC-1 pancreatic cancer
cells with IC50 values that are 2.3- to 24-fold less than that
of the normal human hepatic cells (HL-7702). The pan
caspase inhibitor zVAD-fmk did not inhibit the cytotoxic
activity of ART. Electron microscopy of ART-treated cells
revealed severe cytoplasmic swelling and vacuolization,
swollen and internally disorganized mitochondria, dilation
(but not fragmentation) of the nuclei without chromatin
condensation, and cell lysis, yielding a morphotype that is
typical of oncosis. The ART-treated cells exhibited a loss
of mitochondrial membrane potential (m) and ART-
induced cell death was inhibited in the presence of the reac-
tive oxygen species (ROS) scavenger N-acetyl-cysteine
(NAC). Importantly, ART produced a dose-dependent
tumor regression in an in vivo pancreatic cancer xenografts
model. The in vivo antitumor activity of ART was similar
to that of gemcitabine. Taken together, our study suggests
that ART exhibits antitumor activity against human pancre-
atic cancer via a novel form of oncosis-like cell death, and
that ART should be considered a potential therapeutic
candidate for treating pancreatic cancer.
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Introduction
Pancreatic cancer is one of the most malignant tumors with
a very poor prognosis. Its high mortality can be attributed
to late diagnosis and poor response to chemo- and radiation
therapies [1]. The 5-year survival rate is <5%, and only
approximately one in Wve of the 10% of patients with
resectable disease survive 5 years [2]. Systemic chemother-
apy remains the principle treatment option for patients with
advanced pancreatic cancer. However, pancreatic cancer is
extraordinarily resistant to genotoxic therapy [3]. Currently,
gemcitabine-based therapy is the standard treatment for
unresectable, locally advanced/metastatic pancreatic can-
cer, but yields a median survival duration of only 6 months
[4]. Hence, there is an urgent need to develop eVective che-
motherapeutic agents for pancreatic cancer.
Artesunate (ART) is a derivative of artemisinin
(Fig. 1A), the principle active component of the Chinese
herb Artemisia annua L. Artesunate, which is approved for
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the treatment of multidrug-resistant malaria and has an
excellent safety proWle [5]. In addition to its anti-malarial
activity, ART has been shown to have cytotoxic eVects on a
number of human cancer cell types, including leukemia,
colon cancer, and melanoma cells [6]. Moreover, ART has
recently been shown to possess cytotoxicity against hepa-
toma cells and ovarian cancer cells in vitro and in vivo [7,
8]. Mechanisms that might explain the antitumor activity of
ART include induction of apoptosis of T leukemia cells [9],
anti-proliferative or anti-angiogenic eVects in xenografted
Kaposi’s sarcoma in mice [10], inhibition of growth of C6
glioma cells by increasing levels of reactive oxygen species
[11] or DNA damage [12]. However, little is known about
the eVects of ART on pancreatic cancers. Therefore, it is
worth determining whether the known cytotoxic activity of
ART extends to pancreatic cancer.
Here we Wrst evaluated the therapeutic potential of ART
against pancreatic cancer cells in vitro and in vivo, and then
proceeded to examine the underlying mechanism involved
in ART-mediated cell death. Flow cytometry and electron
microscopy were employed to characterize ART’s mecha-
nism of action related to mitochondrial dysfunction and
reactive oxygen species (ROS) generation. In particular, we
examined whether ART-treated cancer cells exhibit a
proWle consistent with an oncosis-like (non-apoptotic)
mechanism.
Materials and methods
Cell culture and reagents
Panc-1 (ATCC No. CRL-1469), BxPC-3 (ATCC No. CRL-
1687) and CFPAC-1 (ATCC No. CRL-1918) human pan-
creatic cancer cell lines were obtained from the American
Type Culture Collection (Manassas, VA). Normal human
hepatic cells HL-7702 (GNHu 6) were obtained from the
Cell Collection of Chinese Academy of Science (Shanghai,
China). Panc-1 and BxPC-3 cell lines were maintained in
RMPI1640, the CFPAC-1 cell line was grown in IMDM,
and HL-7702 cells were cultured in DMEM. All media
were supplemented with 10% fetal bovine serum (GIBCO,
Invitrogen Corp., Carlsbad, CA), 100 U/ml penicillin and
100 g/ml streptomycin and maintained at 37°C in the
presence of 5% CO2.
ART (Guilin Pharmaceutical Co. Ltd, Guangxi, China)
were freshly prepared in 5% sodium bicarbonate solution and
diluted in cell cultures to the indicated Wnal concentrations.
Cisplatin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT), Hoechst 33258, 6-carboxy-2,7-
dichloroXuorescein diacetate (DCFH-DA), the antioxidant
N-acetyl-cysteine (NAC), and the pan caspase inhibitor
zVAD-fmk were purchased from Sigma Chemical Co.
(St. Louis, MO). Gemcitabine was purchased from Lilly
France S.A.S (Fegersheim, France).
Cytotoxicity assay
Cells were plated in triplicate in 96-well plates (Falcon,
BD, Franklin Lakes, NJ) at 104 cells per well. Twenty-four
hours later, the cells were treated with ART for 48 h at the
concentrations indicated. Cell viability was measured using
an MTT assay. Cell viability numbers were determined by
calculating the average counts from three wells and the
experiment was repeated in triplicate.
Determination of apoptosis
Cells were plated in triplicate and treated with ART or cis-
platin for the indicated periods of time. Apoptotic cell death
Fig. 1 Cytotoxic eVects of ART 
on human pancreatic cancer 
cells. A Chemical structure of 
ART. B Panc-1, BxPC-3, CF-
PAC-1, and normal (HL-7702) 
hepatic cells were treated with 
the indicated concentrations of 
ART for 48 h. Mean values for 
three independent cell viability 
MTT assays are plotted. C 
Phase-contrast micrographs of 
Panc-1 cells treated with vehicle 
(a, control), 50 mol/l ART for 
24 h (b), 50 mol/l ART for 48 h 
(c) or 50 mol/l cisplatin for 
48 h (d) are shown. All images 
captured at 100£ magniWcationCancer Chemother Pharmacol (2010) 65:895–902 897
123
was examined by two parameters: cell and nuclear mor-
phology by Xuorescence microscopy (Axiovert-200M
microscope, Zeiss) after intravital staining with 5 g/ml
Hoechst 33258 and DNA fragmentation analysis by Xow
cytometry according to Nicoletti’s method [13]. BrieXy,
cells were resuspended in a buVer containing 0.1% (w/v)
sodium citrate, 0.1% (v/v) Triton X-100, and 50 g/ml pro-
pidium iodide (Sigma, St. Louis, MO). After incubation at
4°C in the dark for at least 16 h, apoptotic nuclei were
quantiWed by a Xow cytometer (Epics XL, Beckman Coul-
ter).
Electron microscopy
Cells were Wxed with 3% glutaraldehyde in 0.1 M cacodyl-
ate buVer for 15 min at room temperature. The cells were
scraped, transferred to an Eppendorf tube, and centrifuged
at 400£g for 5 min. The pellets were washed with 0.1 M
cacodylate buVer, postWxed in 2% osmium tetroxide, dehy-
drated in acetone, and embedded in araldite. Ultra-thin sec-
tions stained with uranyl acetate and lead citrate were
examined using a transmission electron microscope (CM-
10, Philips).
Caspase inhibition assay
To determine whether caspase is involved in the eVects of
ART, a caspase inhibition assay was carried out with the
pan-caspase inhibitor zVAD-fmk dissolved in DMSO,
according to the manufacturer’s instructions. BrieXy, Panc-
1 cells (3 £ 105 cells per well) were seeded in a 60-mm
dish and incubated overnight. zVAD-fmk (40 mol/l) was
then added to the cells, and 2 h later, the ART treatment
was administered. After 24 h, cell viability was determined
by MTT assay as described above. The viability of
untreated cells in the presence of diluted DMSO was
regarded as 100%.
Mitochondrial membrane potential (m) assays
Mitochondria were selectively probed with potential-sensi-
tive JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-benzim-
idazolylcarbocyanine iodide; Molecular Probes, Invitrogen
Corp., Carlsbad, CA). Cells were harvested after a 24-h
exposure to ART and centrifuged at 400£g for 5 min, and
the cell pellet was resuspended in 0.5 ml of JC-1 solution
(10 g/ml) for 10 min. The cells were then washed and
resuspended in PBS for Xow cytometry analysis. JC-1
exhibits  m-dependent accumulation in mitochondria,
indicated by a shift in its Xuorescence emission from green
to red as J-aggregates form. Mitochondrial depolarization is
thus indicated by a decrease in the red/green Xuorescence
ratio [14].
Measurement of reactive oxygen species
Production of ROS was determined using DCFH-DA and
Xow cytometry analysis as described previously [15]. This
cell-permeating, non-Xuorescent probe is oxidized by ROS
and converted into a Xuorescent product, 2,7-dichloroXu-
orescein, which can be measured by Xow cytometry. Panc-
1 cells (3 £ 105 cells per well) were seeded into 60-mm
plates and incubated overnight. The cells were incubated
for 1 h in DCFH-DA (10 mol/l) in FCS-free medium. The
probe was then removed and the cells were rinsed with
PBS. Rinsed cells were then incubated for 5 h in fresh
medium with ART at the Wnal indicated concentrations.
Finally, the cells were trypsinized, resuspended in PBS, and
subjected to Xow cytometry analysis.
In vivo xenograft studies
Female BALB/c athymic nude mice (4–6 weeks old) were
purchased from the Shanghai Laboratory Animal Center of
the Chinese Academy Sciences. Panc-1 cells were grown,
harvested, washed with PBS, and resuspended in DMEM.
Mice were injected subcutaneously (s.c.) into each posterior
Xank region with approximately 6.0 £ 106 cells. Xenografts
were allowed to grow, and treatment was started when the
injected cell mass reached a mean volume of 130 mm3. After
tumor formation, the mice were randomized into Wve groups
(N = 5 per group), and administered ART (25, 50, or 100 mg/
kg/day, i.p.), saline only in the case of the untreated control
group, or gemcitabine (100 mg/kg/day i.p. every 3 days) in
the case of the chemotherapy control group. Tumor growth
was monitored twice weekly. The length (l) and the width
(w) of the tumors were measured using a slide caliper and the
volume (V) of each tumor was calculated as follows:
V = l £ w2/2. The mice were sacriWced and the tumors were
excised after 20 days of treatment.
Statistical analysis
All quantitative assays were performed in triplicate. The
results are expressed as means § SD. Pairs of datasets were
compared using Student’s t test. SigniWcant diVerences
were considered to exist for those probabilities below 5%
(P<0.05).
Results
ART demonstrates cytotoxic activity against human 
pancreatic cancer cells
The dose-dependent cell proliferation curves showed that ART
exhibited cytotoxicity in all pancreatic cell lines examined898 Cancer Chemother Pharmacol (2010) 65:895–902
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(Panc-1, BxPC-3, and CFPAC-1) in a micromolar dose range.
The IC50 values for Panc-1, BxPC-3 and CFPAC-1 cells were
26.76, 279.3, and 142.8 mol/l, respectively (Fig. 1B). Impor-
tantly, ART was 2.3- to 24-fold less cytotoxic to normal
human hepatic cells (HL-7702) (IC50 = 643.3 mol/l) than to
the cancer cells, suggesting that ART induces selective cyto-
toxicity in human pancreatic cancer cells.
Under the phase-contrast microscope, pancreatic cancer
cells showed a dramatic morphological change 24 h after treat-
ment with 50 mol/l ART. SpeciWcally, the ART-treated cells
had intense swelling and vacuolization, which culminated in
cell lysis by 48 h after the treatment. No morphological charac-
teristics of apoptosis were observed in the ART-treated cells.
On the contrary, cells exposed to cisplatin (50 mol/l) for 48 h
did exhibit morphological features of apoptosis, such as cell
membrane blebbing, cell shrinkage, increased cytoplasm gran-
ules, and detachment from the plate (Fig. 1C).
ART induces caspase-independent and non-apoptotic cell 
death in Panc-1 cells
Hoechst 33258 staining of Panc-1 cells treated with 50 mol/
l ART for 48 h demonstrated that the ART treatment did not
induce biochemical features of apoptosis such as nuclear
condensation and chromatin fragmentation. In contrast, cells
treated with cisplatin showed chromatin fragmentation, a
familiar characteristic of apoptosis (Fig. 2a). Consistent with
these morphological observations, the propidium iodide-
based Xow cytometric DNA fragmentation assay indicated
that ART-treated cells did not produce a hypodiploid peak (a
hallmark of apoptosis), though a hypodiploid peak was
observed for the cisplatin-treated cells (Fig. 2b). Further-
more, pretreatment (2 h) of ART-treated Panc-1 cells with
the general caspase inhibitor z-VAD-fmk did not inhibit
ART’s cytotoxic activity (Fig. 2c), suggesting that ART
induced caspase-independent cell death in Panc-1 cells.
ART-induced cell death has ultrastructural features 
of oncosis
Electron microscopy conWrmed the control Panc-1 cells
have intact cellular morphology with ultrastructurally nor-
mal nuclei and organelles (Fig. 3a). In contrast, Panc-1
cells treated with 50 mol/l ART for 48 h exhibited cyto-
plasmic swelling with a dramatic disruption of cytoarchi-
tecture, including numerous small and large cytoplasmic
vacuoles as well as swollen and internally disorganized
mitochondria. The most prominent nuclear changes were
dilation of the nuclei, irregular clumping of chromatin, and
the appearance of cleared chromatin-free nuclear domains
(Fig. 3b). High magniWcation electron micrographs of
ART-treated Panc-1 cells revealed severely damaged mito-
chondria with decreased matrix density and swelling of
cristae, but no evidence of autophagy (Fig. 3c). The swol-
len cytoplasm contained remnants of vesiculated organelles
and some ruptures of the plasma membrane could be
observed up to the Wnal stages of cell death (Fig. 3d). This
cytoplasmic degradation was not accompanied by an over-
all chromatin condensation. These morphologic features are
consistent with a type of cell death termed oncosis [16–19].
ART induced change in m and ROS-mediated cell 
death in Panc-1 cells
Mitochondrial m was measured in cells stained with the
cationic dye JC-1. As shown in Fig. 4a, Panc-1 cells
Fig. 2 Characterization of ART-induced cell death. a Hoechst 33258
Xuorescent staining revealed nuclear and chromatin modiWcations dur-
ing ART induced cell death (200£ magniWcation). Panc-1 cells were
treated with vehicle (control), 50 mol/l ART, or 50 mol/l cisplatin
for 48 h. b Propidium iodide-based Xow cytometric DNA fragmenta-
tion assay data indicated that ART (50 mol/l at indicated times) does
not cause DNA fragmentation in Panc-1 cells. c MTT cell viability
assay data indicated that ART-induced cell death is not blocked by
inhibition of caspase activity with the pan-caspase inhibitor z-VAD-
fmk (40 mol/l, started 2 h before ART treatment for a period of 48 h).
Parallel cultures treated with cisplatin (50 mol/l for 48 h) were used
as controls. Values correspond to means § SD of triplicates obtained
in three independent experimentsCancer Chemother Pharmacol (2010) 65:895–902 899
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subjected to the 50 mol/l ART treatment for 6 h exhibited
an increase in green and a decrease in red JC-1 Xuores-
cence, indicating a loss of m. A marked increase in the
number of cells with decreased red Xuorescence indicative
of mitochondrial depolarization was found 24 h after ART
treatment (Fig. 4a).
The DCFH-DA assay for ROS generation revealed 1.6-
fold and 4.49-fold increases in Xuorescence in cells treated
with 50 and 200 mol/l ART, respectively; these Wndings
demonstrate a dose-dependent increase in ROS production
in response to ART treatment (Fig. 4b, left). Pretreatment
of Panc-1 cells for 30 min with the ROS scavenger NAC
after 5 h of exposure to ART almost completely inhibited
ROS generation (Fig. 4b, right) and markedly reduced
ART’s cytotoxic eVect (Fig. 4c), suggesting ROS genera-
tion could mediate ART-induced cell death.
In vivo antitumor activity of ART
As shown in Fig. 5a, ART induced a dose-dependent inhi-
bition of Panc-1 tumor growth. Daily administration of 25,
50 and 100 mg/kg ART (i.p.) in established Panc-1 xeno-
grafts mode (average tumor volume = 130 mm3) sup-
pressed tumor growth by 33, 44, and 65%, respectively
(P < 0.01 versus saline controls), at the end of the study
(day 20). Gemcitabine treatment (100 mg/kg i.p., twice
weekly) reduced tumor growth on day 20 by 70%; this
result did not diVer signiWcantly from the result seen with
100 mg/kg ART (Fig. 5a).
The body weights of ART-treated and control mice did
not diVer from each other. ART at the highest dose tested
(100 mg/kg) was well tolerated and did not cause any
observable toxicity. In comparison, gemcitabine treatment
was associated with a 25% reduction in body weight
(Fig. 5b). In addition, mice treated with gemcitabine were
weak and inactive, and two of the gemcitabine-treated mice
died on day 18.
Discussion
The present study demonstrated that micromolar doses of
ART can induce selective cytotoxic activity against human
pancreatic cancer cells. Electron microscopy observations
revealed that ART initiates a death process characterized by
marked swelling and a series of profound morphological
alterations, including numerous small and large cytoplas-
mic vacuoles, swollen and internally disorganized mito-
chondria, dilation of the nuclei without chromatin
condensation, and ultimately cell lysis. These morphologic
observations in the absence of features characteristic of
apoptosis, together with the Wnding that caspase inhibition
did not aVect ART-induced cell death, suggest that ART
induces a non-apoptosis type of cell death, just like oncosis
[16–19]. ART induced cell death was associated with a loss
of m, but could be blocked by inhibition of ROS gener-
ation, suggesting that the mechanism of pancreatic cancer
cell death caused by ART may involve mitochondrial dys-
function and generation of ROS. Furthermore, ART pro-
duced a dose-dependent tumor regression in an in vivo
pancreatic cancer xenograft model. The in vivo antitumor
activity of ART was similar to that of gemcitabine. More-
over, ART has been approved by the State Food and Drug
Administration of China for the treatment of multidrug-
resistant malaria and has an excellent safety proWle. Thus,
our data suggest that, relative to established drugs, ART
could be a safer and more eYcacious anticancer agent for
treatment of human pancreatic cancer.
The term oncosis was adapted by Majno and Joris [18]
to describe a mechanism of cell death distinct from the
more extensively studied apoptosis. While apoptosis is
characterized by cell shrinkage, chromatin condensation,
and formation of apoptotic bodies, oncosis is characterized
by rapid cell swelling, organelle swelling, membrane
Fig. 3 ART-mediated cell death features resemble ultrastructural fea-
tures of oncosis-like cell death. a Control cells showing intact ultra-
structurally normal nuclei (N) and cellular organelles, and an absence
of cytoplasmic vacuolation. b Low-magniWcation survey electron
micrograph illustrating numerous large and small cytoplasmic vacu-
oles, dilation of nuclei with cleared nuclear domains free of chromatin
in 50 mol/l ART-treated cells. c High-magniWcation electron micro-
graph illustrating swollen mitochondria (M) with disintegrated cristae
and decreased matrix density. d Severe dilation of nuclei, swollen
mitochondria, and ruptured plasma membrane late in the process of
ART-treated cell death. MagniWcations: 1800£ (a, b and d); 5000£ (c)900 Cancer Chemother Pharmacol (2010) 65:895–902
123
permeability, and cell lysis [18, 19]. Cell death by apopto-
sis leads to necrosis with karyorrhexis, whereas cell death
by oncosis may result in necrosis with karyolysis [17, 18].
It is often assumed that chemotherapy drugs induce cell
death through apoptotic mechanisms [20]. Indeed, studies
have suggested that ART can trigger apoptotic cell death in
various tumor cell lines [7–9, 21, 22], but the eVect of ART
on pancreatic cancer is still unknown. The present data for
the Wrst time indicate that ART induces a unique type of
cell death in pancreatic cancer cells via an atypical non-
apoptotic pathway. Numerous factors including both a
distinct morphological proWle (cell swelling instead of
shrinking) and biochemical Wndings support our view that
ART induces oncosis-like cell death rather than apoptosis.
First, ART did not induce nuclear condensation and chro-
matin fragmentation. Second, ART-treated cells did not
exhibit the hypodiploid peak that is a hallmark of apoptotic
cells subjected to the iodide-based Xow cytometric DNA
fragmentation assay. Third, the pan caspase inhibitor
zVAD-fmk did not inhibit the cytotoxic activity of ART.
Although ART was demonstrated to have cytotoxic
eVects on tumor cells a decade ago [23], the molecular
mechanisms by which ART exerts its anti-tumor activity
have yet to be elucidated clearly. Given the severe destruc-
tion of cell organelles, including mitochondria, observed by
electron microscopy, it is reasonable to consider whether
ART cytotoxicity involves an alteration of mitochondrial
function. On the other hand, ART is a sesquiterpene lactone
that exerts its anti-malarial activity by generation of organic
free radicals through cleavage of the endoperoxide bridge
within its active moiety [24, 25]. The radical molecules can
cause macromolecular damage by alkylating and poisoning
essential malarial proteins [25]. Our data indicate that ART
causes a loss of m and induces cell death by generation
of ROS. This conclusion is supported by the Wnding that the
ROS scavenger NAC blocked ROS generation and, conse-
quently, inhibited ART-induced cell death.
While apoptosis is increasingly well deWned at the
molecular level, the biochemical determinants of necrotic/
oncotic cell death remain less well deWned. Recent research
Fig. 4 ART-induced cell death involves loss of mitochondrial mem-
brane potential and generation of ROS. a Flow cytometry analysis of
JC-1-stained Panc-1 cells incubated with 50 mol/l ART for 6, 12, or
24 h. Mitochondrial depolarization is reXected by a red to green shift
in Xuorescence emission. Data from one representative experiment out
of three are shown. b DCFH-DA assay and Xow cytometry analysis
revealed a dose-dependent increase in ROS production in response to
50 mol/l (dark line) or 100 mol/l (light line) ART treatment for 5 h.
The shaded histograms were generated from untreated control data
(left). Pretreatment of the cells with the antioxidant NAC (15 mM) for
30 min markedly inhibited ROS production (right).  c MTT assays
showed that a 48-h incubation with the antioxidant NAC (15 mM)
inhibited ART cytotoxicity of Panc-1 cells. Data are shown as means
§ SD of three independent experimentsCancer Chemother Pharmacol (2010) 65:895–902 901
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suggests that oncosis is associated with intracellular events
such as enhanced generation of ROS, swelling of mitochon-
dria, ATP depletion, failure of Ca2+ homeostasis, activation
of some proteases (e.g., calpains and cathepsins), lysosomal
rupture, and ultimately plasma membrane rupture [26].
Although each of these events alone is not speciWcally
responsible for oncosis, it is possible that a collection of
these events in an organized, programmed cascade of self-
destruction deWnes oncosis. Apoptosis and oncosis have
some features in common, such as the mitochondrial per-
meability transition and loss of m; the ultimate fate of
cells is mostly due to the intensity and duration of the death
signal and the cell’s genetic and metabolic status [27]. Cells
in an aerobic environment are constantly generating ROS.
While physiologic levels of ROS can serve as signaling
molecules to regulate transcription, excessive production of
ROS leads to oxidative stress, damage of intracellular mol-
ecules and organelles, and ultimately necrosis [28].
Accordingly, the triggering of ROS mediated oncosis-like
cell death induced by ART may become an alternative
approach to eradicate tumor cells, particularly tumor cells
with defects in apoptosis pathway.
Recently, Youns et al. [29] showed that ART inhibited
growth and induced apoptosis of human pancreatic cancer
cells and the eVect was more prominent with the poorly
diVerentiated MiaPaCa-2 cells. Also, ART was identiWed as
a novel topoisomerase II alpha inhibitor that inhibits pan-
creatic cancer cell growth through modulation of multiple
signaling pathways. It is likely that diVerent types of pan-
creatic cancer cells have particular molecular actions pecu-
liar to their cell death process. Further studies examining
the biochemical and molecular mechanisms of ART-
induced cell death should provide a deeper understanding
of the nature and characteristics of the cytotoxic eVect of
ART.
In summary, the present results show that ART exhibits
potent antitumor activity against human pancreatic cancer
cells in vitro and tumor xenografts in vivo. It displays a dis-
tinctive mode of action in which it induces ROS-mediated
oncosis-like cell death in pancreatic cancer cells. The Wnd-
ings in this study may underline the potential utility of
induction of ROS-mediated oncosis as a novel therapeutic
strategy for the treatment of cancer. More studies are
needed to fully characterize the anti-tumor action of ART,
including the identiWcation of its primary target(s) and the
basis for its preferential eVect on tumor cells.
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